医薬品原薬CDMO市場：医薬品、製品、合成、ワークフロー、用途別-2025-2030年世界予測

医薬品原薬CDMO市場の2023年の市場規模は1,148億5,000万米ドルで、2024年には1,264億2,000万米ドルに達すると予測され、CAGR 10.38％で成長し、2030年には2,293億9,000万米ドルに達すると予測されています。

医薬品原薬（API）CDMO（医薬品開発・製造受託機関）市場は、製薬企業にとって重要な医薬品開発・製造プロセスのアウトソーシングに焦点を当てています。APIは医薬品の生物学的に活性な成分であるため、CDMO市場はこれらの物質の合成、プロセス開発、大量生産によって定義されます。CDMOの必要性は、製薬会社が業務を合理化し、コストを削減し、中核となる研究開発活動に集中する必要性から生じています。原薬の用途は循環器、腫瘍、神経など様々な治療分野に及び、最終用途市場には製薬会社、バイオテクノロジー企業、ジェネリック医薬品メーカーなどが含まれます。現在、主な成長要因としては、生物製剤やバイオシミラーの進歩、慢性疾患の増加、個別化医療に対する需要の高まりなどが挙げられます。新たなビジネスチャンスは、より環境に優しい製造プロセスへのシフトと、プロセス最適化のための人工知能の統合にあります。しかし、厳しい規制要件、サプライチェーンの混乱、競争の激化といった課題は、市場の成長を抑制する可能性があります。また、アウトソーシングに伴う品質上の懸念や知財リスクの可能性も制約要因として挙げられます。こうした課題に対処し機会を活用するためには、連続製造プロセスやナノテクノロジー応用の革新が大きな成長の道筋を示す可能性があります。また、ビッグデータ解析や機械学習を活用したデジタル・トランスフォーメーションによるプロセス効率化も、新たな研究開発・事業開発分野を開拓します。API CDMO市場は、市場シェアを獲得するための重要な戦略として共同研究や戦略的提携が浮上しており、ダイナミックな性質を示しています。R&Dと技術適応への持続的な投資により、企業はこの進化する市場情勢において競争力を高めることができます。

市場力学：急速に進化する医薬品原薬CDMO市場の主要市場インサイトを公開

医薬品原薬CDMO市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • ジェネリック医薬品需要の高まりとバイオ医薬品消費の増加
  • 低分子の成長、原薬（API）の複雑化
  • 標的がん治療やその他の治療に対する需要の高まり
• 市場抑制要因
  • アウトソーシング時のコンプライアンスに関する問題
• 市場機会
  • 医薬品原薬CDMOのための研究開発投資の増加
  • がん治療薬研究の高度化
• 市場の課題
  • 原薬CDMOに対する厳しい規制遵守要件

ポーターの5つの力：医薬品原薬CDMO市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：医薬品原薬CDMO市場における外部からの影響の把握

外部マクロ環境要因は、医薬品原薬CDMO市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析医薬品原薬CDMO市場における競合情勢の把握

医薬品原薬CDMO市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス医薬品原薬CDMO市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、医薬品原薬CDMO市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨医薬品原薬CDMO市場における成功への道筋を描く

医薬品原薬CDMO市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • ジェネリック医薬品の需要増加とバイオ医薬品の消費増加
    • 低分子の成長、医薬品有効成分（API）の複雑性の増大
    • 標的がんやその他の医療治療に対する需要の高まり
  • 抑制要因
    • アウトソーシング時のコンプライアンスに関連する問題
  • 機会
    • 医薬品原薬CDMOの研究開発投資の増加
    • 腫瘍薬調査の高度化が進む
  • 課題
    • API CDMOに対する厳格な規制遵守要件
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 医薬品原薬CDMO市場薬物別

• ジェネリック
• 革新的

第7章 医薬品原薬CDMO市場：製品別

• 抗体薬物複合体
• 非常に強力な有効医薬品成分
• 伝統的な医薬品有効成分

第8章 医薬品原薬CDMO市場合成別

• バイオテクノロジー
• 合成

第9章 医薬品原薬CDMO市場：ワークフロー別

• 臨床
• 商業用

第10章 医薬品原薬CDMO市場：用途別

• 心臓血管
• 糖尿病
• 緑内障
• ホルモン
• 腫瘍学

第11章 南北アメリカの医薬品原薬CDMO市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の医薬品原薬CDMO市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの医薬品原薬CDMO市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• 5N Plus
• A. R. Life Sciences Pvt. Ltd.
• AbbVie Inc.
• abcr GmbH
• Biocon Limited
• Boehringer Ingelheim International GmbH
• Cambrex Corporation
• Catalent, Inc.
• Corden Pharma International GmbH
• Curia Global, Inc.
• Dr. Reddy's Laboratories Ltd.
• Evonik Industries AG
• IOL Chemicals and Pharmaceuticals Limited
• Jungbunzlauer Suisse AG
• Lonza Group Ltd.
• Lupin Limited
• Minafin Group
• Mylan Inc.
• Olon S.p.A.
• Piramal Group
• PMC Group, Inc.
• Polpharma SA
• Recipharm AB
• Samsung Biologics
• SEQENS
• Siegfried AG
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceutical Industries Ltd.
• Tiefenbacher API+Ingredients GmbH & Co. KG
• Xellia Pharmaceuticals ApS by Novo Holdings A/S

LIST OF FIGURES

• FIGURE 1. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET RESEARCH PROCESS
• FIGURE 2. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET DYNAMICS
• TABLE 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GENERICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY INNOVATIVE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANTIBODY DRUG CONJUGATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOTECH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY HORMONAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 43. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 45. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 46. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 70. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 72. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 73. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 75. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 76. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 77. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 78. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 130. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 150. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 155. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 160. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 161. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 162. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 163. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 164. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 170. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 175. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 180. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 181. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 182. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 183. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 184. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 185. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 186. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 187. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 188. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 189. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 190. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 195. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 205. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 210. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 215. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 220. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 225. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 230. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 235. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 236. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET, FPNV POSITIONING MATRIX, 2023

The Active Pharmaceutical Ingredients CDMO Market was valued at USD 114.85 billion in 2023, expected to reach USD 126.42 billion in 2024, and is projected to grow at a CAGR of 10.38%, to USD 229.39 billion by 2030.

The active pharmaceutical ingredients (API) CDMO (Contract Development and Manufacturing Organization) market focuses on the outsourcing of drug development and manufacturing processes which are crucial for pharmaceutical companies. APIs are the biologically active components in drugs; thus, the CDMO market is defined by the synthesis, process development, and large-scale production of these substances. The necessity for CDMOs arises from the need for pharmaceutical companies to streamline operations, reduce costs, and focus on core R&D activities. Applications of APIs span across various therapeutic areas such as cardiovascular, oncology, and neurology, with end-use markets including pharmaceutical companies, biotechnology firms, and generic drug manufacturers. Currently, key growth factors include advancements in biologics and biosimilars, increasing prevalence of chronic diseases, and the rising demand for personalized medicine. Emerging opportunities are grounded in the shifts towards greener manufacturing processes and artificial intelligence integration for process optimization. However, challenges such as stringent regulatory requirements, supply chain disruptions, and high competition may restrain market growth. Limitations also include the potential for quality concerns and IP risks associated with outsourcing. To address these challenges and leverage opportunities, innovations in continuous manufacturing processes and nanotechnology applications could present significant growth avenues. The digital transformation with the use of big data analytics and machine learning for enhanced process efficiencies also opens up new research and business development fields. The API CDMO market showcases a dynamic nature with collaborations and strategic partnerships emerging as key strategies to capture market share. With sustained investment in R&D and technology adaptation, companies can enhance their competitive edge in this evolving market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Active Pharmaceutical Ingredients CDMO Market

The Active Pharmaceutical Ingredients CDMO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising demand for generic drugs and increasing consumption of biopharmaceuticals
  • Growth of small molecules, rising active pharmaceutical ingredient (API) complexity
  • Growing demand for targeted cancer and other medical treatments
• Market Restraints
  • Issues associated with compliances while outsourcing
• Market Opportunities
  • Increasing R&D investment for active pharmaceutical ingredients CDMO
  • Proliferating sophistication in oncology drug research
• Market Challenges
  • Stringent regulatory compliance requirements for API CDMO

Porter's Five Forces: A Strategic Tool for Navigating the Active Pharmaceutical Ingredients CDMO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Active Pharmaceutical Ingredients CDMO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Active Pharmaceutical Ingredients CDMO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Active Pharmaceutical Ingredients CDMO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Active Pharmaceutical Ingredients CDMO Market

A detailed market share analysis in the Active Pharmaceutical Ingredients CDMO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Active Pharmaceutical Ingredients CDMO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Active Pharmaceutical Ingredients CDMO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Active Pharmaceutical Ingredients CDMO Market

A strategic analysis of the Active Pharmaceutical Ingredients CDMO Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Active Pharmaceutical Ingredients CDMO Market, highlighting leading vendors and their innovative profiles. These include 5N Plus, A. R. Life Sciences Pvt. Ltd., AbbVie Inc., abcr GmbH, Biocon Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Corden Pharma International GmbH, Curia Global, Inc., Dr. Reddy's Laboratories Ltd., Evonik Industries AG, IOL Chemicals and Pharmaceuticals Limited, Jungbunzlauer Suisse AG, Lonza Group Ltd., Lupin Limited, Minafin Group, Mylan Inc., Olon S.p.A., Piramal Group, PMC Group, Inc., Polpharma SA, Recipharm AB, Samsung Biologics, SEQENS, Siegfried AG, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Tiefenbacher API + Ingredients GmbH & Co. KG, and Xellia Pharmaceuticals ApS by Novo Holdings A/S.

Market Segmentation & Coverage

This research report categorizes the Active Pharmaceutical Ingredients CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug, market is studied across Generics and Innovative.
• Based on Product, market is studied across Antibody Drug Conjugate, Highly Potent Active Pharmaceutical Ingredient, and Traditional Active Pharmaceutical Ingredient.
• Based on Synthesis, market is studied across Biotech and Synthetic.
• Based on Workflow, market is studied across Clinical and Commercial.
• Based on Application, market is studied across Cardiovascular, Diabetes, Glaucoma, Hormonal, and Oncology.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising demand for generic drugs and increasing consumption of biopharmaceuticals
    • 5.1.1.2. Growth of small molecules, rising active pharmaceutical ingredient (API) complexity
    • 5.1.1.3. Growing demand for targeted cancer and other medical treatments
  • 5.1.2. Restraints
    • 5.1.2.1. Issues associated with compliances while outsourcing
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing R&D investment for active pharmaceutical ingredients CDMO
    • 5.1.3.2. Proliferating sophistication in oncology drug research
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory compliance requirements for API CDMO
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Active Pharmaceutical Ingredients CDMO Market, by Drug

• 6.1. Introduction
• 6.2. Generics
• 6.3. Innovative

7. Active Pharmaceutical Ingredients CDMO Market, by Product

• 7.1. Introduction
• 7.2. Antibody Drug Conjugate
• 7.3. Highly Potent Active Pharmaceutical Ingredient
• 7.4. Traditional Active Pharmaceutical Ingredient

8. Active Pharmaceutical Ingredients CDMO Market, by Synthesis

• 8.1. Introduction
• 8.2. Biotech
• 8.3. Synthetic

9. Active Pharmaceutical Ingredients CDMO Market, by Workflow

• 9.1. Introduction
• 9.2. Clinical
• 9.3. Commercial

10. Active Pharmaceutical Ingredients CDMO Market, by Application

• 10.1. Introduction
• 10.2. Cardiovascular
• 10.3. Diabetes
• 10.4. Glaucoma
• 10.5. Hormonal
• 10.6. Oncology

11. Americas Active Pharmaceutical Ingredients CDMO Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Active Pharmaceutical Ingredients CDMO Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Active Pharmaceutical Ingredients CDMO Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. 5N Plus
• 2. A. R. Life Sciences Pvt. Ltd.
• 3. AbbVie Inc.
• 4. abcr GmbH
• 5. Biocon Limited
• 6. Boehringer Ingelheim International GmbH
• 7. Cambrex Corporation
• 8. Catalent, Inc.
• 9. Corden Pharma International GmbH
• 10. Curia Global, Inc.
• 11. Dr. Reddy's Laboratories Ltd.
• 12. Evonik Industries AG
• 13. IOL Chemicals and Pharmaceuticals Limited
• 14. Jungbunzlauer Suisse AG
• 15. Lonza Group Ltd.
• 16. Lupin Limited
• 17. Minafin Group
• 18. Mylan Inc.
• 19. Olon S.p.A.
• 20. Piramal Group
• 21. PMC Group, Inc.
• 22. Polpharma SA
• 23. Recipharm AB
• 24. Samsung Biologics
• 25. SEQENS
• 26. Siegfried AG
• 27. Sun Pharmaceutical Industries Limited
• 28. Teva Pharmaceutical Industries Ltd.
• 29. Tiefenbacher API + Ingredients GmbH & Co. KG
• 30. Xellia Pharmaceuticals ApS by Novo Holdings A/S